ELANE and colorectal carcinoma: In this study, we evaluated and demonstrated NE in serum as a putative biomarker for the diagnosis of CRC, and blocking NE activity using sivelestat or other NE inhibitors/blockers may provide a new line of therapeutic drugs to limit CRC progression.